For adults in the intensive care unit (ICU) with septic shock, intravenous fluid restriction does not result in fewer deaths at 90 days than standard intravenous fluid therapy, according to a study published online June 17 ...
Jun 17, 2022
0
8
Pfizer's COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.
Jun 2, 2022
0
1
The replication-deficient Vaccinia virus vaccine (JYNNEOS) is recommended over the replication-competent Vaccinia virus vaccine ACAM2000 for individuals with occupational exposure to orthopoxvirus, according to research ...
May 31, 2022
0
1
Patients with multidrug-resistant HIV-1 infection receiving the capsid inhibitor lenacapavir have a greater reduction in viral load than those receiving placebo, according to a study published in the May 12 issue of the New ...
May 12, 2022
0
12
Early tracheostomy does not significantly improve the rate of survival without severe disability at six months for patients with severe stroke receiving mechanical ventilation, according to a study published online May 4 ...
May 11, 2022
0
2
The diameter of the thoracic aorta is a biomarker for heart attacks and other adverse cardiovascular events in women and men, according to a new study published in the journal Radiology.
Apr 12, 2022
0
10
Adverse drug events (ADEs), injuries related to drug-related medical interventions, are considered some of the most prevalent types of health-care-related harm. Given that these events are costly and often morbid, artificial ...
Jan 19, 2022
0
8
(HealthDay)—Steroids reduce the risk for major adverse kidney outcomes in people with high-risk immunoglobulin A nephropathy (IgAN), but full-dose methylprednisolone increased the risk for serious adverse events, according ...
Nov 16, 2021
0
2
(HealthDay)—Sotrovimab reduces the risk for disease progression in high-risk patients with mild-to-moderate COVID-19, according to a study published online Oct. 27 in the New England Journal of Medicine.
Oct 29, 2021
0
6
The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been approved for first-line ...
Oct 4, 2021
0
0
